Advertisement

Multiple Myeloma: Treatment is Getting Individualized

  • M. B. Agarwal
Review Article

Abstract

Multiple myeloma (MM) is a heterogeneous disease with varied outcome. The novel agents including two major classes of drugs; the immunomodulatory drugs and the proteasome inhibitors with unprecedented response rates, have replaced conventional chemotherapy. With monoclonal antibodies on the horizon, outcome of this disorder will further improve. Progression in risk stratification systems has made it possible to predict the disease course as well as outcome in myeloma patients with disease categorization into low to high risk. In addition, detection of minimal residual disease by serum free light chain assay, flow cytometry, molecular techniques like polymerase chain reaction and positron emission tomography scan is playing an important role in modifying the treatment. An extensive research in the disease biology has improved our knowledge regarding interplay between myeloma cells and elements of the bone marrow microenvironment which contribute to sustain proliferation and survival as well as de novo drug resistance. Again, insight into the role of genetic and epigenetic interactions in MM has exposed new molecular targets. All these have opened the gateway for novel therapeutic strategies with focus on risk based individualized therapy.

Keywords

Myeloma Personalized Treatment Risk Stratification Novel 

Notes

Acknowledgments

Professional medical writing support and editorial assistance was provided by DiagnoSearch Life Sciences (P) Ltd., funded by Bristol-Myers Squibb.

Compliance with Ethical Standards

Conflict of Interest

The author did not receive financial compensation for authoring the manuscript.

References

  1. 1.
    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al (2009) Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 84(12):1095–1110PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Ghalaut PS, Chaudhuri S, Singh R (2013) Recent advances in diagnosis and management of multiple myeloma: an update. In: The Association of Physicians of India, Medicine Update 2013, Section 10 Hematology, Chapter 80, pp 360–365Google Scholar
  4. 4.
    Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al (2007) SEER Cancer Statistics Review, 1975–2004. National Cancer Institute, Bethesda [online]. Available from http://seer.cancer.gov/csr/1975_2004/. Accessed Nov 2012
  5. 5.
    Programme National Cancer Registry (2005) Two year report of the population based cancer registries 1999–2000. Indian Council of Medical Research, New DelhiGoogle Scholar
  6. 6.
    Kumar L, Verma R, Radhakrishnan VR (2010) Recent advances in the management of multiple myeloma. Natl Med J India 23(4):210–218PubMedGoogle Scholar
  7. 7.
    Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86–89CrossRefPubMedGoogle Scholar
  8. 8.
    Forgeson GV, Selby P, Lakhani S, Zulian G, Viner C, Maitland J et al (1988) Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer 58:469–473PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842–854CrossRefPubMedGoogle Scholar
  10. 10.
    Greipp PR, Miguel JS, Durie BG, Crowley JJ, Barlogie B, Bladé J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420CrossRefPubMedGoogle Scholar
  11. 11.
    Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B et al (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117(18):4696–4700PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Niels WCJ, Donk VD, Sonneveld P (2014) Diagnosis and risk stratification in multiple myeloma. Hematol Oncol Clin N Am 28:791–813CrossRefGoogle Scholar
  13. 13.
    Girnius S, Munshi NC (2013) Individualized therapy in multiple myeloma: are we there? Semin Oncol 40(5):567–576CrossRefPubMedGoogle Scholar
  14. 14.
    Flactif M, Zandecki M, Laï JL, Bernardi F, Obein V, Bauters F et al (1995) Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 9:2109–2114PubMedGoogle Scholar
  15. 15.
    Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S et al (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28:269–277CrossRefPubMedGoogle Scholar
  16. 16.
    Ross FM, vet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O’Connor S et al (2012) Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97(8):1272–1277PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL et al (2009) Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27:4585–4590PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Broyl A, Hose D, Lokhorst H, Knegt Y, Peeters J, Jauch A et al (2010) Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 16(14):2543–2553CrossRefGoogle Scholar
  19. 19.
    Chi J, Ballabio E, Chen X, Kušec R, Taylor S, Hay D et al (2011) MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 6:23PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Anderson KC (2012) The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30:445–452CrossRefPubMedGoogle Scholar
  21. 21.
    Munshi NC, Anderson KC (2013) New strategies in the treatment of multiple myeloma. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-12-1881 Google Scholar
  22. 22.
    Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A et al (2011) Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk 11(1):44–49CrossRefPubMedGoogle Scholar
  23. 23.
    Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S et al (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27:5008–5014CrossRefPubMedGoogle Scholar
  24. 24.
    Rajkumar SV, Gahrton G, Bergsagel PL (2011) Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 118(12):3205–3211PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A et al (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30:1953–1959CrossRefPubMedGoogle Scholar
  26. 26.
    Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M et al (2015) Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 12:286–295. doi: 10.1038/nrclinonc.2014.239 CrossRefPubMedGoogle Scholar
  27. 27.
    Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28(12):2077–2084CrossRefPubMedGoogle Scholar
  28. 28.
    Munshi NC, Anderson KC (2013) Minimal residual disease in multiple myeloma. J Clin Oncol 31(20):2523–2526CrossRefPubMedGoogle Scholar
  29. 29.
    Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R et al (2014) Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123(20):3073–3079PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr et al (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25:1121–1128CrossRefPubMedGoogle Scholar
  31. 31.
    Bartel TB, Haessler J, Brown TLY, Shaughnessy JD Jr, van Rhee F, Anaissie E et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114:2068–2076PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Puente PDL, Muz B, Azab F, Luderer M, Azab AK (2014) Molecularly targeted therapies in multiple myeloma. Hindawi Publishing Corporation Leukemia Research and Treatment, Article ID 976567. doi: 10.1155/2014/976567
  33. 33.
    Dimopoulos K, Gimsing P, Gronbaek K (2014) The role of epigenetics in the biology of multiple myeloma. Blood Cancer Journal 4:e207PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540–545PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Jagannath S, Dimopoulos MA, Lonial S (2010) Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leuk Res 34:1111–1118CrossRefPubMedGoogle Scholar
  36. 36.
    Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L et al (2007) Targeting aurora kinases as therapy in multiple myeloma. Blood 109:3915–3921PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C et al (2007) Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138:783–791CrossRefPubMedGoogle Scholar
  38. 38.
    Khan SA, Cohen AD (2011) Experimental approaches in the treatment of multiple myeloma. Ther Adv Hematol 2(4):213–230PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Siegel D, Jagannath S, Vesole DH, Borello I, Mazumder A, Mitsiades C et al (2011) A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma 52:2308–2315CrossRefPubMedGoogle Scholar
  40. 40.
    Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M et al (2010) Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 150:428–437PubMedCentralPubMedGoogle Scholar
  41. 41.
    Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S et al (2007) Neutralizing B cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 13:5903–5909CrossRefPubMedGoogle Scholar
  42. 42.
    Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L et al (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66:6675–6682CrossRefPubMedGoogle Scholar
  43. 43.
    Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA et al (2011) RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 117:3847–3857PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2:927–937CrossRefPubMedGoogle Scholar
  45. 45.
    Kroger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H et al (2013) Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogenic tandem transplantation in multiple myeloma. Biol Blood Marrow Transpl 19:398–404CrossRefGoogle Scholar
  46. 46.
    Sugumar D, Keller J, Vij R (2015) Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmgenomics Pers Med 8:23–33PubMedCentralPubMedGoogle Scholar
  47. 47.
    Fouquet G, Bories C, Guidez S, Renaud L, Herbaux C, Javed S et al (2014) Expert reviews pomalidomide for multiple myeloma. Expert Rev Hematol. Early online, 1–13 (2014). Available from: http://szpiczak.org/lang/aktualnosci/komunikaty/pdf/rok_2014/17474086_2014_966074.pdf
  48. 48.
    Richardson PG, Laubach JP, Munshi NC, Anderson KC (2014) Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematol Am Soc Hematol Educ Progr 1:255–261CrossRefGoogle Scholar
  49. 49.
    Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25(1):91–101PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Xie Z, Chng WJ (2014) MMSET: role and therapeutic opportunities in multiple myeloma. BioMed Res Int, Article ID 636514Google Scholar
  51. 51.
    Misso G, Zappavigna S, Castellano M, Rosa GD, Martino MT, Tagliaferri P (2013) Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opin Biol Ther 13(1):S95–S109CrossRefPubMedGoogle Scholar
  52. 52.
    Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M et al (2010) Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24(10):1769–1778CrossRefPubMedGoogle Scholar
  53. 53.
    Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G (2010) Clinical impact of chromosomal aberrations in multiple myeloma. J Intern Med. doi: 10.1111/j.1365-2796.2010.02324.x PubMedGoogle Scholar
  54. 54.
    Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98(7):2229–2238CrossRefPubMedGoogle Scholar
  55. 55.
    Rajkumar SV (2012) Doublets, triplets or quadruplets on novel agents in the treatment of newly diagnosed myeloma. ASH Educ Book 1:354–361. doi: 10.1182/asheducation-2012.1.354 Google Scholar
  56. 56.
    Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P et al (2015) Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. doi: 10.1111/ejh.12491 Google Scholar
  57. 57.
    Leow CC, Gerondakis S, Spencer A (2013) MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J 3:e105. doi: 10.1038/bcj.2013.1 CrossRefGoogle Scholar
  58. 58.
    Herath NI, Rocques N, Garancher Eychène A, Pouponnot C (2014) GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer J 4:e175. doi: 10.1038/bcj.2013.67 PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Biran N, Jagannath S, Chari A (2013) Risk stratification in multiple myeloma, part 1: characterization of high-risk disease. Clin Adv Hematol Oncol 11(8):489–503PubMedGoogle Scholar
  60. 60.
    Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandemstem-cell transplantation. Blood 108:1724–1732PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Shaughnessy J (2005) Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10(Suppl 1):117–126CrossRefPubMedGoogle Scholar
  62. 62.
    Yu W, Li J, Chen L (2014) Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis. Int J Clin Exp Med 7(11):4051–4062PubMedCentralPubMedGoogle Scholar
  63. 63.
    Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV et al (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118(17):4519–4529CrossRefPubMedGoogle Scholar
  64. 64.
    Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C et al (2008) Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 49(5):890–895CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2015

Authors and Affiliations

  1. 1. Department of HaematologyBombay Hospital Institute of Medical SciencesMumbaiIndia

Personalised recommendations